Research Article

Effect of Parecoxib Sodium Preemptive Analgesia on the Recovery Period of General Anesthesia in Patients Undergoing Glioma Resection

Lijuan Zhu,¹ Hui Guo,² Tao Zheng,³ and Jing Zhu ¹

¹Department of Anesthesiology, Shaanxi Provincial People’s Hospital, Xi’an 710068, Shaanxi, China
²Department of Anesthesiology, Xi’an International Medical Center Hospital, Xi’an 710100, Shaanxi, China
³Department of Neurosurgery, Xi’an International Medical Center Hospital, Xi’an 710100, Shaanxi, China

Correspondence should be addressed to Jing Zhu; jingchengyou238844@163.com

Received 31 December 2021; Revised 26 January 2022; Accepted 15 February 2022; Published 13 June 2022

Academic Editor: Xueliang Wu

Copyright © 2022 Lijuan Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To investigate the effect of parecoxib sodium preemptive analgesia on postoperative complications and postoperative recovery of patients undergoing glioma resection. Methods. A total of 200 eligible patients with low-grade gliomas in the functional brain area scheduled for an awake craniotomy between January 2017 and December 2020 were reviewed. The subjects were divided into two groups: the study group (n = 100) given dexmedetomidine plus parecoxib sodium for pre-emptive analgesia 30 minutes preoperatively, and the control group (n = 100) receiving dexmedetomidine alone. Venous blood was collected before surgery, at the time of postoperative recovery, and 24 hours after operation, mean artery pressure (MAP) and heart rate (HR) were recorded during surgery. Sedation satisfaction, agitation rate, numerical pain score (NRS), postoperative complications, mini-mental state examination (MMSE) scores, quality of life (QoL) scores, and incidence of adverse events were also investigated after the surgery. Results. There were no significant differences in operation time, awakening time, intraoperative awakening time, and extubation time between the two groups (P > 0.05). Compared with the control group, the ΔMAP (7.26 ± 2.21 versus 5.78 ± 2.36 mmHg) and the ΔHR (11.35 ± 3.66 versus 8.84 ± 2.47 beats/min) were significantly lower in the study group (P < 0.05). Compared with the control group, the satisfaction was higher and agitation rate was lower in the study group (P < 0.05). The incidence of intracranial infection and pulmonary infection decreased after operation (P < 0.05). The NRS of the study group was remarkably lower than the control group at 12 hours postoperatively Preoperative MMSE score and QoL score showed no statistical difference (P > 0.05), while postoperative MMSE and QoL scores showed statistical difference (P < 0.05). Conclusion. This study suggests that parecoxib sodium can significantly improve the level of sedation and analgesia in patients undergoing glioma resection, reduce the incidence of intracranial infection and pulmonary infection.

1. Introduction

Glioma is a malignant tumor originating from neurons and glial cells. It is the most common primary intracranial tumor, which accounts for 40%-50% of intracranial tumors [1]. Surgical resection is the most preferred treatment for glioma, which removes most of the tumor cells, effectively relieves patients’ symptoms, and provides pathological support for further treatment [2]. Studies have shown that some neurosurgery patients have unconscious limb movements during anesthesia recovery and even self-removal of tracheal catheter, which in serious cases leads to catheter shedding, asphyxia, limb fracture, and increased perioperative wind risk [3]. Parecoxib sodium can reduce the afferent center of injurious stimulus, effectively reduce postoperative pain, and then reduce the incidence of postoperative agitation, which has important clinical value for patients to safely pass through the recovery period of anesthesia [4]. At present, the application of dexmedetomidine and parecoxib sodium in surgery has been reported in literature, but there are a few reports on the effects of the combined application of dexmedetomidine and parecoxib...
2. Materials and Methods

2.1. Baseline Data. From January 2017 to December 2020, we conducted a retrospective analysis of 200 patients with low-grade glioma in the functional brain region (WHO I-II) in the neurosurgery department of our hospital.

2.2. Inclusion and Exclusion Criteria

2.2.1. Inclusion Criteria. (1) Patients aged 35–70 years, a Karnofsky performance score (KPS) > 60 points; (2) patients with a confirmed diagnosis of glioma by clinical and MRI examinations, to receive an awake craniotomy for glioma resection; (3) patients with American Society of Anesthesiologists (ASA) grade I-II for anesthesia risk assessment; (4) patients undergoing craniotomy for the first time with no previous history of radiotherapy.

2.2.2. Exclusion Criteria. (1) Patients with other malignant tumors; (2) known or suspected drug or alcohol abuse, and pregnancy; (3) allergy to NSAIDs or any of the drugs used in the study and coexisting diseases that could affect the reliability of assessments; (4) a history of significant cardiac, pulmonary, hepatic, or renal disease; (5) patients with mental disorders that prevented cooperation in completing intraoperative anesthesia assessment.

2.3. Anaesthesia and Analgesia. Patients in both groups underwent the same preoperative preparation, including routine monitoring of the electrocardiogram, pulse oximetry, invasive blood pressure, and bispectral index, and received awake craniotomy. A loading dose of 0.5 μg/kg dexmedetomidine was administered, anesthesia was inducted with propofol 2 mg/kg and remifentanil 0.1 μg/(kg-min) that were administered intravenously, and rocuronium bromide 0.6 mg/kg was given via intravenous push. The lungs were ventilated mechanically with a tidal volume of 8–12 mL/kg at a frequency of 12–14 bpm to perform end-tidal carbon dioxide between 35 and 45 mmHg. Anesthesia was maintained with an effector compartment target concentration of 2.5 pg/ml at propofol target-controlled infusion, and remifentanil was infused at a rate of 0.1 μg/(kg-min). Patients in the study group were given 40 mg of parecoxib sodium intravenously for 30 min preoperatively and those of the control group were given the same dose of saline.

2.4. Data Collection. Demographic and intraoperative characteristics of patients such as age, sex distribution, weight, body mass index (BMI), operative time, recovery time, extubation time, and perioperative complications (including respiratory depression, nausea, vomiting, and shivering) were recorded. In addition, intraoperative wake-up time, and intraoperative range of MAP and HR were recorded (ΔMAP = MAP max–MAP min, ΔHP = HP max–HP min).

The Ramsay sedation score was used to assess the degree of intraoperative sedation during the wake-up period, and the numerical pain score (NRS) was used to assess the degree of wake-up analgesia of patients. Ramsay sedation score: 1 point: restless and irritable; 2 points: quiet and cooperative; 3 points: drowsy and able to follow instructions; 4 points: sleeping and arousable; 5 points: sluggish response to calling; 6 points: deep sleeping and unawakenable to calling. 2–4 points were classified as satisfactory sedation, and 5–6 points were classified as oversedation. The NRS scores at the time of postoperative recovery (T1), 2 hours postoperatively (T2), 12 hours postoperatively (T3), 24 hours postoperatively (T4), and 48 hours postoperatively (T5), were obtained by the patients circling the scores corresponding to the pain, where 0 points indicated no pain and 10 points indicated severe pain. Postoperative complications were recorded, including length of stay, 30-day readmission rate, intraoperative blood transfusion, and cardiopulmonary complications.

Intraoperative wake-up agitation was recorded and graded, in which grade 0 was quiet and cooperative; grade 1 was mild irritability, agitation, and intermittent moaning during stimuli; grade 2 was agitation and continuous moaning without stimuli, requiring immobilization of upper limbs; grade 3 was intensive struggling and agitation, attempting to extubate, and requiring immobilization on all limbs.

2.5. Postoperative Complications. The incidence of pulmonary and intracranial infections was significantly reduced with parecoxib, but the length of hospital stay, intraoperative blood transfusion, and other cardiopulmonary complications were not significantly different (P < 0.05).

2.6. Cognitive Function and Quality of Life Evaluation. The mini-mental state examination (MMSE) [5] scale was used to evaluate the cognitive function of the patients preoperatively and 1 month postoperatively. The MMSE scale consists of 11 items in five domains: orientation, memory, attention, language, and visual-spatial skills, with a total score of 30 points, and the higher the score, the better the cognitive function. The quality of life (QoL) scale [6] was used to assess the quality of life of patients preoperatively and 1 month postoperatively, and the QoL consisted of 12 domains, with a total of 5 points for each domain and a total of 60 points. The higher the score, the better the quality of life.

2.7. Statistical Analysis. All data analyses were performed using the SPSS 23.0 and visualized into required graphics via GraphPad Prism 9.0 software. The continuous variables with normal distribution were presented as mean and standard deviation, and the continuous variables with skewed distribution were presented as median (25th, 75th). Categorical
variables were compared using χ² test. Intergroup comparison was analyzed by repeated-measure analysis of variance. In all analyses, \( P < 0.05 \) was considered statistically significant.

3. Results

3.1. Demographic Characteristics of the Patients Included. A total of 200 patients were included for randomization. Baseline data of the 100 patients in the two groups are given in Table 1. All eligible patients showed similar baseline characteristics including age, gender, BMI, ASA classification, and WHO grading \( (P > 0.05) \) (Table 1).

3.2. Perioperative Indices. In the control group, the intraoperative wake-up duration was \( 30.45 \pm 3.03 \) min, the ΔMAP was \( 7.26 \pm 2.21 \) mmHg, and the ΔHR was \( 11.35 \pm 3.66 \) times/min; in the study group, the above indicators were \( 29.42 \pm 4.33 \) min, \( 5.78 \pm 2.36 \) mmHg, and \( 8.84 \pm 2.47 \) times/min, respectively. Similar intraoperative wake-up durations were observed in both the groups \( (P > 0.05) \). Dexmedetomidine plus pre-emptive analgesia with parecoxib sodium resulted in significantly milder changes in MAP and HR versus dexmedetomidine \( (P < 0.05) \) (Table 2). There was no significant difference in operation time, postoperative recovery time, and extubation time with parecoxib sodium \( (P > 0.05) \) (Table 3).

3.3. Sedation and Agitation in Intraoperative Wake-Up. In the control group, there were 13 cases of inadequate sedation and 5 cases of oversedation, with a sedation satisfaction rate of 82.00% \( (82/100) \); in the study group, there were 7 cases of inadequate sedation and 1 cases of oversedation, with a sedation satisfaction rate of 92.00% \( (92/100) \). The sedation satisfaction rate of the study group was higher than that of the control group, and the difference was statistically significant \( (P > 0.05) \) (Table 4).

In the control group, there were 88 cases of agitation grade 0, 3 cases of grade 1, 5 cases of grade 2, and 4 cases of grade 3, with an agitation rate of 12.00% \( (12/100) \); in the study group, there were 90 cases of agitation grade 0, 4 cases of grade 1, 3 cases of grade 2, and 3 cases of grade 3, with an agitation rate of 10.00% \( (10/100) \) (Table 5).

3.4. Postoperative Pain. After a slight increase in T2, the NRS scores steadily decreased from T3 to T4 in both the groups. The NRS scores of the study group were significantly lower than those of the control group at all time points from T2 to T4 \( (P < 0.05) \) (Figure 1).

3.5. Postoperative Complications. Postoperative complications are given in Table 6

3.5.1. Cognitive Function and Quality of Life. Preoperative MMSE and QOL scores of the two groups showed no statistical difference. Compared with the control group, the value of MMSE decreased and the quality of life score increased after operation, with statistical significance \( (P < 0.05) \) (Table 7).

3.6. Perioperative Adverse Events. The study group had 5 cases of nausea and vomiting, and 5 cases of headache, with an incidence of adverse events of 10.00% \( (10/100) \). The control group had 6 cases of nausea and vomiting, and 3 cases of headache, with an incidence of adverse events of 9.00% \( (9/100) \). No new safety signals were identified. The two groups obtained a similar incidence of adverse events \( (P > 0.05) \) (Table 8).

4. Discussion

Neurosurgery usually takes a long time, requires a large amount of anesthetic drugs, and has a high incidence of restlessness during recovery from anesthesia. A strong stress response may increase blood pressure and heart rate, which may cause serious consequences and have a serious negative impact on perioperative safety [7]. Therefore, reducing stress response and agitation is of great clinical value to patients. In the review process, the performance of all eligible patients in intraoperative wake-up was favorable and the glioma resection was uneventful, which evidenced the promising analgesic effects of dexmedetomidine. In glioma resection, real-time patient feedback is essential to achieve the maximum excision of diseased tissue while preserving functional brain areas [8]. Agitation and inadequate sedation during intraoperative wake-up are associated with complications such as seizures, vomiting, and aspiration [9]. Cyclooxygenase (COX) is a key enzyme that catalyzes arachidonic acid (AA) to produce various prostaglandins (PGs). There are mainly two types of isoenzymes, namely COX-1 and COX-2 [10]. COX-1 is mainly involved in normal vasodilatory and contractile functions, gastric mucosal protection, gastrointestinal blood flow regulation, and maintenance of normal renal function [11]. COX-2 is an inducible enzyme, which usually exists at low levels in tissues but can be induced and produced in large quantities in the case of infection and injury. COX-2 is mainly expressed in neurons of cerebral cortex, hippocampus, amygdala, and spinal dorsal horn [12]. COX-2 expression was significantly increased in microglia and astrocytes under continuous neuroinflammatory response [13]. When inflammation occurs in the nervous system, COX-2 plays an important role in synaptic plasticity, neural development, learning and memory acquisition, and neurotransmitter transmission [14]. A large number of studies have shown that COX-2 expression is upregulated and play a key pathophysiological role in central nervous system diseases such as stroke, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, and schizophrenia [15].
with parecoxib sodium significantly improved the alleviation of MAP and HR fluctuations, increased sedation satisfaction, and reduced the incidence of agitation compared with dexmedetomidine alone. At present, there are a few literature studies about the effects of the combined use of parecoxib sodium and dexmedetomidine on restlessness in patients during recovery. The results of this study suggest that the combined use of the two can further reduce the incidence of restlessness and play a synergic role.

The mechanism may be related to the inhibition of prostaglandin production by inhibiting coxidase in peripheral and central nervous system, thus reducing peripheral and central nervous system sensitization caused by harmful stimulus and reducing inflammatory response. Cui et al. showed that COX-2 was upregulated in glioma tissues [17]. As a COX-2 inhibitor, parecoxib sodium can rapidly recast immune molecules to enhance immune function by limiting COX-2-driven immune evasion [18]. This may

| Table 1: Baseline characteristics of the patients. |
|-----------------------------------------------|
| Control group (n = 100) | Study group (n = 100) | t/χ² | P |
| Age (x ± s, years) | 39.45 ± 7.04 | 40.26 ± 6.83 | 0.758 | 0.363 |
| Gender | | | 3.089 | 0.079 |
| Male | 69 | 57 | | |
| Female | 31 | 43 | | |
| BMI (kg/m²) | 21.83 ± 2.21 | 21.93 ± 3.81 | 1.017 | 0.327 |
| ASA classification | | | 2.426 | 0.119 |
| I | 42 | 53 | | |
| II | 58 | 47 | | |
| WHO grading | | | 0.184 | 0.668 |
| I | 59 | 56 | | |
| II | 41 | 44 | | |

| Table 2: Intraoperative wake-up (x ± s). |
|-----------------------------------------|
| Control group (n = 100) | Study group (n = 100) | ΔMAP (mmHg) | ΔHR (times/min) |
| Intraoperative wake-up duration (min) | 30.45 ± 3.03 | 29.42 ± 4.33 | 7.21 ± 2.11 | 5.73 ± 2.26 |
| | | | 11.42 ± 3.66 | 8.81 ± 2.47 |
| t | 0.463 | 0.348 | | |
| P | 0.758 | 0.001 | | |

| Table 3: Perioperative indices (x ± s, min). |
|---------------------------------------------|
| Control group (n = 100) | Study group (n = 100) | Operative time | Recovery time | Extubation time |
| | | 305.64 ± 30.23 | 304.31 ± 32.36 | 21.83 ± 2.36 | 20.03 ± 2.61 |
| | t | 1.122 | 0.324 | | |
| | P | 0.367 | 0.085 | | |

| Table 4: Sedation in intraoperative wake-up (n = 100, %). |
|---------------------------------|
| Satisfied sedation (2~4) | Unsatisfied sedation |
| | Inadequate sedation (1) | Oversedation (5~6) | Sedation satisfaction rate (%) |
| Control group (n = 100) | 82 | 13 | 5 | 82.00 |
| Study group (n = 100) | 92 | 7 | 1 | 92.00 |
| χ² | 4.421 | | | 0.036 |

| Table 5: Agitation in intraoperative wake-up (n = 100, %). |
|---------------------|
| Agitation grading |
| | Grade 0 | Grade 1 | Grade 2 | Grade 3 | Agitation rate (%) |
| Control group (n = 100) | 88 | 3 | 5 | 4 | 12.00 |
| Study group (n = 100) | 90 | 4 | 3 | 3 | 10.00 |
| χ² | | 0.204 | | 0.051 |

The mechanism may be related to the inhibition of prostaglandin production by inhibiting coxidase in peripheral and central nervous system, thus reducing peripheral and central nervous system sensitization caused by harmful stimulus and reducing inflammatory response. Cui et al. showed that COX-2 was upregulated in glioma tissues [17]. As a COX-2 inhibitor, parecoxib sodium can rapidly recast immune molecules to enhance immune function by limiting COX-2-driven immune evasion [18]. This may
account for the decrease in the lung and intracranial infections with parecoxib. Perfect immune function is an important condition for maintaining neural activity. Under pathological conditions, cellular inflammatory response will lead to upregulation of the expression of proinflammatory cytokines and proinflammatory enzymes, thus promoting the neuronal cell death caused by inflammation [19]. With parecoxib, the MMSE score was reduced, indicating improved cognitive function. The incidence of adverse events was similar in the two groups, indicating that parecoxib sodium had no inhibition on COX-1 and had little inhibition on gastrointestinal mucosa.

5. Conclusion

In conclusion, the above two anesthesia schemes can be safely used for glioma resection, dexmedetomidine combined with parecoxib sodium has a lower agitation score
during awakening, mild changes in blood pressure and heart rate during intraoperative awakening, and a significant decrease in the incidence of complications of intracranial infection and pulmonary infection during postoperative hospitalization. Systematic and large-sample prospective studies on the long-term prognosis of glioma patients with the combination of these two drugs are still lacking. Therefore, on the basis of this study, the influence of two anesthesia schemes on the incidence of postoperative complications of other types of intracranial tumors can be further explored.

Data Availability

All data generated or analyzed during this study are included in this published article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

Lijuan Zhu and Hui Guo contributed equally to this work.

References

[1] X. Gu, X. Tan, J. Chen, J. Wang, Y. Lu, and L. Zhang, “The clinical effect of dexmedetomidine combined with parecoxib sodium on sedation, antianxiety and prevention of intubation stress in patients undergoing functional endoscopic sinus surgery: a randomised controlled trial,” BMC Anesthesiology, vol. 20, no. 1, p. 166, 2020.
[2] G. Acosta-Gonzalez, M. Ouseph, K. Lombardo, S. Lu, J. Glickman, and M. B. Resnick, "Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression," Human Pathology, vol. 83, pp. 115–123, 2019.
[3] M. Stål Nacke, K. Solowska, T. Bergenheim, and R. L. Sjöberg, "Phenomenology of glioma resection in the dorsal medial frontal cortex," Acta Neurologica Scandinavica, vol. 142, pp. 216–220, 2020.
[4] G. Liu, Y. Ma, Y. Chen, Y. Zhuang, Y. Yang, and X. Tian, “Effects of parecoxib after pancreaticoduodenectomy: a single center randomized controlled trial,” International Journal of Surgery, vol. 90, Article ID 105962, 2021.
[5] E. Jin, S. Li, M. Ren, Q. Hu, Y. Gu, and K. Li, "Boron affects immune function through modulation of splenic T lymphocyte subsets, cytokine secretion, and lymphocyte proliferation and apoptosis in rats," Biological Trace Element Research, vol. 178, no. 2, pp. 261–275, 2017.
[6] S. Oberndorfer and M. Hutterer, "Palliative care in glioma management," Current Opinion in Oncology, vol. 31, no. 6, pp. 548–553, 2019.
[7] A. J. Gogos, J. S. Young, R. A. Morshad, S. L. Hervey-Jumper, and M. S. Berger, "Awake glioma surgery: technical evolution and nuances," Journal of Neuro-Oncology, vol. 147, no. 3, pp. 515–524, 2020.
[8] H.-W. Sim, E. R. Morgan, and W. P. Mason, “Contemporary management of high-grade gliomas,” CNS Oncology, vol. 7, no. 1, pp. 51–65, 2018.
[9] Z. Chen, N. Dai, S. Lin, and G. Zhou, “Impact of dexmedetomidine on intraoperative wake-up tests in patients undergoing spinal surgery,” Journal of PeriAnesthesia Nursing, vol. 33, no. 4, pp. 448–452, 2018.
[10] R. Liu, S. Wu, C. Guo et al., "Ibuprofen exerts antiepileptic and neuroprotective effects in the rat model of pentylenetetrazol-induced epilepsy via the COX-2/NLRP3/IL-18 pathway," Neurochemical Research, vol. 45, no. 10, pp. 2516–2526, 2020.
[11] Y. Yan, F. Tong, and J. Chen, "Endogenous BMP-4/ROS/COX-2 mediated IPC and resveratrol alleviated brain damage," Current Pharmaceutical Design, vol. 25, no. 9, pp. 1030–1039, 2019.
[12] F. Rocha Santos Passos, L. Heimfarth, B. Souza Monteiro et al., "Oxidative stress and inflammatory markers in patients with COVID-19: potential role of RAGE, HMGB1, GFAP and COX-2 in disease severity," International Immunopharmacology, vol. 104, Article ID 108502, 2022.
[13] J. Cui and J. Jia, “Natural COX-2 inhibitors as promising anti-inflammatory agents: an update,” Current Medicinal Chemistry, vol. 28, no. 18, pp. 3622–3646, 2021.
[14] H. D. T. Torrance, R. M. Pearse, and M. J. O’Dwyer, “Does major surgery induce immune suppression and increase the risk of postoperative infection?” Current Opinion in Anaesthesiology, vol. 29, no. 3, pp. 376–383, 2016.
[15] K. C. S. Roballo and J. Bushman, “Evaluation of the host immune response and functional recovery in peripheral nerve autografts and allografts,” Transplant Immunology, vol. 53, pp. 61–71, 2019.
[16] M. Li and Z. Zheng, “Protective effect of parecoxib sodium against ischemia reperfusion-induced intestinal injury,” Molecular Medicine Reports, vol. 24, no. 5, p. 776, 2021.
[17] X. Cui, N. Cui, J. Pan, and X. Sun, “Expression of RhoA and COX-2 and their roles in the occurrence and progression of brain glioma,” Pakistan Journal of Pharmaceutical Sciences, vol. 34, no. 1(Special), pp. 397–401, 2021.
[18] K. Song, L. Li, G. Sun, and Y. Wei, "MicroRNA-381 regulates outgrowth by targeting the tumor vasculature," Experimental and Therapeutic Medicine, vol. 15, no. 5, pp. 4557–4563, 2018.
[19] M. Wagemakers, G. E. van der Wal, R. Caberres et al., "COX-2 inhibition combined with radiation reduces orthotopic glioma outgrowth by targeting the tumor vasculature," Translational Oncology, vol. 2, no. 1, pp. 1–7, 2009.